GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 3 380 JPY 5.13% Market Closed
Market Cap: 169.4B JPY
Have any thoughts about
GNI Group Ltd?
Write Note

GNI Group Ltd
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GNI Group Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
GNI Group Ltd
TSE:2160
Other
-ÂĄ3.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Other
-ÂĄ19.3m
CAGR 3-Years
-2 580%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Other
-ÂĄ2m
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Foods International Co Ltd
TSE:2929
Other
-ÂĄ12m
CAGR 3-Years
-14%
CAGR 5-Years
35%
CAGR 10-Years
N/A
S
StemRIM Inc
TSE:4599
Other
-ÂĄ1k
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Other
-ÂĄ16.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
169.2B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 956.28 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

What is GNI Group Ltd's Other?
Other
-3.1B JPY

Based on the financial report for Sep 30, 2024, GNI Group Ltd's Other amounts to -3.1B JPY.

Back to Top